The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma

Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors within the ubiquitin proteasome pathway, with an aim to achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Crawford, Lisa J., Campbell, David C., Morgan, Jonathan J., Lawson, Michelle A., Down, Jennifer M., Chauhan, Dharminder, McAvera, Roisin M., Morris, Treen C., Hamilton, Claudia, Krishnan, Aswini, Rajalingam, Krishnaraj, Chantry, Andrew D., Irvine, Alexandra E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329634/
https://www.ncbi.nlm.nih.gov/pubmed/32523091
http://dx.doi.org/10.1038/s41388-020-1345-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329634/
https://www.ncbi.nlm.nih.gov/pubmed/32523091
http://dx.doi.org/10.1038/s41388-020-1345-x

Ejemplares similares